We studied 40 patients with Crohn's disease (CD), 18 to 60 years of age, of both genders, who were followed up at the IBD outpatient clinic, Gastrocenter - UNICAMP, and who were under continuous and regular use of Infliximab (IFX). The peripheral blood collection was performed before the IFX application. Quantification of serum IFX levels and presence of anti-IFX antibody (ATIs) were performed by the ELISA method - Promonitor®. The endoscopic activity of the disease was defined as CDEIS> 5 or the presence of deep ulcers in at least one intestinal segment analyzed and according to the radiological activity. The study has been approved by the UNICAMP Research Committee CAAE 53097116.2.0000.5404.

No abstract